482 results found

The Thirteenth National People's Congress has released its second draft amendments to the Patent Law for comment on July 3, 2020, which is open for public comments until August 16, 2020.

In January 2022, Estee Lauder (China), the international beauty and skincare company, was fined RMB 2,381,671 (approximately USD 350,000) for false advertising in China.

The drugs claimed in drug invention patents must be approved by the National Medical Products Administration ("NMPA") before entering into market. Due to the long review period for drugs, it is very likely that a patent...

China's State Council issued new Anti-Monopoly Guidelines for the Pharmaceutical Sector (the "Guidelines") effective January 24, 2025.

Multinational pharmaceutical and medical device companies conducting clinical trials in China have been facing new challenges in the year since the Regulation on Human Genetic Resources...

天津で今月9日に開催された「デジタル・スマートでエンパワーメン...

According to the White Paper on China's Intellectual Property Protection in 2021, local courts at all levels across the country received 550,263 first-instance intellectual property cases and concluded 515,861 cases..

The China National Medical Products Administration (NMPA) drug patent linkage measures have not mentioned how to handle the above situation...

On June 20, 2020, the Standing Committee of the National People's Congress (NPC) published its 2020 version of draft amendments to Patent Law (2020 version) for comment.

As we reported in our October 2020 Newsletter, the Fourth Amendment to Chinese Patent Law (the Amendment) will be effective from June 1, 2021.

Like many other offices, the Chinese Patent Office does not grant protection to inventions relating to a method of therapeutic treatment.

On November 28, 2024, China's National Medical Products Administration (NMPA, 国家药品监督管理局), China's equivalent of the U.S. Food and Drug Administration...

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

The China Food and Drug Administration ("CFDA") promulgated a new circular (2017) No.68 related to the promotion of a drug market authorization holder regime ("MAH Regime") work on 21 August 2017...

An executive meeting of the State Council of China was held on April 12, 2018 and presided by Premier Mr. Li Keqiang.

Thanks for the notification from Aaron Wininger of Schwegman Lundberg & Woessner, P.A. , the China State Administration for Market Regulation SAMR announced the finalized...